The abstract is read at the publisher; the summary is JClub's.
In nine recurrent glioblastoma patients, allogeneic CYT-101 CMV-specific T cells plus pembrolizumab showed no dose-limiting toxicities, with OS-6 at 55% and PFS-6 at 11%.
- Why it matters: Glioblastoma’s immunosuppressive microenvironment and PD-1–high tumour-infiltrating CMV-specific T cells may limit checkpoint-sensitive T-cell therapy, creating a need for safer immune-activating combinations.
- What they did: In a phase I 3+3 dose-escalation study, patients received four weekly CYT-101 infusions followed by pembrolizumab, with safety as the primary endpoint and immune correlates plus PFS-6/OS-6 as secondary endpoints.
- The result: CYT-101 induced enhanced global CD4+ and CD8+ T-cell function and donor-derived clonotypes in 6 of 9 participants with T-cell repertoire remodelling, while no objective responses were observed.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.